Zydus Lifesciences Limited has expanded its companion diagnostics portfolio with the launch of two innovative continuous glucose monitoring devices. The company announced on March 12, 2026, the introduction of Diasens™ and GlucoLive™, next-generation CGM systems that integrate artificial intelligence-powered analytics with comprehensive remote care capabilities.

Product Features and Technology

The new CGM devices represent a significant advancement in glucose monitoring technology for Indian patients. Unlike existing devices in the market that rely on NFC technology requiring manual scanning, Diasens™ and GlucoLive™ automatically stream glucose readings to patients' smartphones every three minutes without any manual intervention.

Strategic Partnership and Digital Integration

Zydus has partnered with Digicare Health Solutions Private Limited (TatvaCare™) to enhance the patient experience through digital integration. The CGM system connects with TatvaCare's proprietary GoodFlip™ app, creating a comprehensive healthcare ecosystem that includes:

• AI-powered report analysis and trend detection
• Personalized diet and exercise coaching
• Doctor consultation services
• Diagnostic lab booking capabilities
• Comprehensive medical record vault
• Real-time alerts for hypo-/hyperglycaemic episodes

Market Context and Healthcare Need

The launch addresses a critical healthcare challenge in India, where the country hosts over 101 million adults living with diabetes according to the ICMR-INDIAB study published in The Lancet Diabetes & Endocrinology. This represents the second-highest diabetes burden globally, with an additional 136 million individuals in the pre-diabetic stage.

Diabetes serves as the leading cause of Chronic Kidney Disease in India, with 25-40% of CKD patients having a diabetes history. The healthcare system currently relies on episodic monitoring through periodic finger-prick tests or laboratory HbA1c checks conducted every three to six months, creating significant gaps in continuous care.

Clinical Benefits and Remote Monitoring

The devices feature a dedicated clinician dashboard that enables healthcare providers to monitor patients remotely and make data-driven treatment adjustments. The AI analytics system detects glucose trends, flags dangerous episodes, and links fluctuations to food and activity patterns, generating actionable insights for both patients and healthcare providers.

Dr. Sharvil Patel, Managing Director of Zydus Lifesciences Limited, emphasized the patient-centric approach: "The launch of Diasens™ and GlucoLive™ strengthen our companion diagnostics portfolio for chronic disease management. Focused on patient-centric convenience and better quality of life, these CGMs powered by AI technology, will give patients real-time access to key glycaemic data on their mobile devices, simplifying monitoring and control."

Technology Integration and Care Ecosystem

The convergence of the CGM devices with TatvaCare's digital platform creates a closed-loop care ecosystem connecting patients, caregivers, and clinicians in real-time. This integration ensures uninterrupted glucose data capture, including critical overnight readings and emergency situations, while providing early intervention capabilities through continuous remote monitoring.

Zydus Lifesciences Limited has announced receiving final approvals from the United States Food and Drug Administration (USFDA) for two generic pharmaceutical products on February 28, 2026. The approvals encompass Ivermectin Tablets USP, 3 mg and Dapsone Tablets USP in both 25 mg and 100 mg strengths, expanding the company's presence in the US generic drug market.

Product Details and Market Potential

The approved products target significant therapeutic areas with established market demand:

Therapeutic Applications

Ivermectin Tablets

Ivermectin Tablets USP, 3 mg serve as prescription anti-parasitic medications with primary indications for treating parasitic worm infections in humans. The drug specifically targets intestinal strongyloidiasis and onchocerciasis, representing the US reference listed drug Stromectol® Tablets, 3 mg.

Dapsone Tablets

Dapsone Tablets USP in 25 mg and 100 mg strengths are indicated for treating leprosy in all forms, including multibacillary and paucibacillary variants, as well as dermatitis herpetiformis. The medication functions as an anti-infective and antibacterial agent, effectively controlling skin lesions associated with dermatitis herpetiformis and managing leprosy symptoms.

Manufacturing and Distribution Strategy

Both pharmaceutical products will be manufactured at Zydus Lifesciences Limited 's formulation manufacturing facilities in Ahmedabad. Ivermectin tablets will be produced at the SEZ facility, while Dapsone tablets will be manufactured at the SEZ-II facility. Distribution for both products will be handled through Viona Pharmaceuticals Inc.

Regulatory Portfolio Expansion

With these latest approvals, the company has strengthened its regulatory portfolio significantly:

*As on December 31, 2025

The combined annual sales potential of USD 23.2 million for both products, based on IQVIA MAT December 2025 data, represents a meaningful addition to the company's US market opportunities. These approvals demonstrate Zydus Lifesciences' continued commitment to expanding its generic pharmaceutical offerings in specialized therapeutic segments.